Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding

BACKGROUND: For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical trials. In systematic reviews on the clinical use of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Eller, P, Pechlaner, C, Wiedermann, CJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1373608/
https://www.ncbi.nlm.nih.gov/pubmed/16420687
http://dx.doi.org/10.1186/1477-9560-4-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1373608/
https://www.ncbi.nlm.nih.gov/pubmed/16420687
http://dx.doi.org/10.1186/1477-9560-4-1

Ejemplares similares